The effects of the new antipsychotic medications on mothers and babies.
Second generation antipsychotics are widely used by thousands of pregnant women worldwide in order to control their psychiatric disorders. The clinical profiles of these drugs have improved, specifically the decreased risk of hyperprolactinemia, which has increased fertility in female patients. However, the reproductive safety of second generation antipsychotics remains undefined and controversial. The aim of this presentation is to synthesize the available evidence-based information into a systematic review of the safety in pregnancy of this group of drugs (in mono-and polytherapy).